Venturi Wealth Management LLC Increases Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Venturi Wealth Management LLC grew its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 28.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,369 shares of the biotechnology company’s stock after purchasing an additional 300 shares during the period. Venturi Wealth Management LLC’s holdings in Repligen were worth $204,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in RGEN. Toronto Dominion Bank increased its holdings in shares of Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC increased its stake in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 105 shares during the last quarter. Diversified Trust Co raised its holdings in Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 106 shares in the last quarter. Finally, CWM LLC lifted its position in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after buying an additional 114 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RGEN. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. UBS Group reduced their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Finally, Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Trading Up 1.3 %

Shares of RGEN stock opened at $150.47 on Thursday. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $141.59 and its two-hundred day moving average is $144.78. The company has a market capitalization of $8.43 billion, a P/E ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the firm posted $0.23 EPS. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. Equities analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.